Kemwell Updates

 

Accelerates Cipla’s global lung leadership agenda

In an exclusive interview with The CSR Journal, Karan Bagaria talks about the growing importance of the Biopharma industry after the COVID-19 pandemic.

Bengaluru-based Kemwell Biopharma, a biologics contract development and manufacturing service provider, is working aggressively on augmenting its existing infrastructure. In addition, the CDMO is exploring strategic partnerships with biopharma players in the ecosystem to fit out its additional capacity which can be executed within 12-15 months.

The CDMO sector has grown and innovated immensely over the years, and technology has acted as a catalyst in this transformational journey

The government plans to develop three mega bulk drug parks, which will be set up at a cost of Rs 14,300 Cr in association with various states to produce chemicals for life-saving drugs and reduce their imports from China.

The company has acquired an Ambr 250, added three single use bioreactors (SUBs) to support process scale-up, preclinical toxicology batch and early cGMP clinical trial supplies at 250L to 1000L scale in its current facility